PharmaCyte Biotech, Inc.
PMCB
$0.9411
$0.00730.78%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 915.10K | 842.10K | 1.01M | 1.17M | 1.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.04M | 960.30K | 1.11M | 1.27M | 1.17M |
| Operating Income | -1.04M | -960.30K | -1.11M | -1.27M | -1.17M |
| Income Before Tax | 11.75M | -3.05M | -1.47M | 23.42M | 1.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.75M | -3.05M | -1.47M | 23.42M | 1.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.75M | -3.05M | -1.47M | 23.42M | 1.35M |
| EBIT | -1.04M | -960.30K | -1.11M | -1.27M | -1.17M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 1.58 | -0.44 | -0.21 | 2.18 | -0.30 |
| Normalized Basic EPS | -0.10 | 0.28 | 0.23 | 0.10 | 0.25 |
| EPS Diluted | 1.58 | -0.44 | -0.21 | 2.18 | -0.30 |
| Normalized Diluted EPS | -0.10 | 0.28 | 0.23 | 0.10 | 0.25 |
| Average Basic Shares Outstanding | 6.85M | 6.96M | 7.64M | 7.87M | 8.35M |
| Average Diluted Shares Outstanding | 6.85M | 6.96M | 7.64M | 7.87M | 8.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |